PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Clinical trials for PULMONARY ALVEOLAR PROTEINOSIS (PAP) explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ALVEOLAR PROTEINOSIS (PAP) trials appear
Sign up with your email to follow new studies for PULMONARY ALVEOLAR PROTEINOSIS (PAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug shows promise for rare immune disorders
Disease control CompletedThis early-phase study tested rituximab, a drug used for rheumatoid arthritis, in 7 adults with rare diseases where the immune system attacks the body's own proteins. The goal was to see if the drug is safe and can help control these hard-to-treat conditions. Participants receive…
Matched conditions: PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 26, 2026 06:58 UTC
-
Rare lung disease study digs into how gene mutation disables cellular cleanup crew
Knowledge-focused CompletedThis study looked at a rare lung condition called pulmonary alveolar proteinosis (PAP) caused by changes in the MARS gene. Researchers wanted to understand why the lungs can't clear out fatty buildup. They took blood samples from 20 children with and without the mutation, grew th…
Matched conditions: PULMONARY ALVEOLAR PROTEINOSIS (PAP)
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC